Alzinova AB (publ) (ALZ.ST)
SEK 1.87
(1.41%)
SEK 1.87
(1.41%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -16.52 Million SEK | -26.25% |
| 2022 | -13.08 Million SEK | -74.04% |
| 2021 | -7.51 Million SEK | -15.71% |
| 2020 | -6.49 Million SEK | -5.2% |
| 2019 | -6.17 Million SEK | -47.43% |
| 2018 | -4.19 Million SEK | -68.28% |
| 2017 | -2.48 Million SEK | 15.75% |
| 2016 | -2.95 Million SEK | 13.2% |
| 2015 | -3.4 Million SEK | -640.91% |
| 2014 | -459.55 Thousand SEK | -38.36% |
| 2013 | -332.14 Thousand SEK | 82.18% |
| 2012 | -1.86 Million SEK | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -4.96 Million SEK | -3.14% |
| 2024 Q2 | -4.76 Million SEK | 3.97% |
| 2023 Q2 | -3.9 Million SEK | 8.52% |
| 2023 Q4 | -4.81 Million SEK | -36.38% |
| 2023 Q1 | -4.27 Million SEK | 10.02% |
| 2023 FY | -16.52 Million SEK | -26.25% |
| 2023 Q3 | -3.52 Million SEK | 9.7% |
| 2022 Q4 | -4.74 Million SEK | -71.68% |
| 2022 Q3 | -2.76 Million SEK | 16.13% |
| 2022 FY | -13.08 Million SEK | -74.04% |
| 2022 Q2 | -3.29 Million SEK | -44.92% |
| 2022 Q1 | -2.27 Million SEK | 7.03% |
| 2021 Q3 | -1.45 Million SEK | 32.49% |
| 2021 FY | -7.51 Million SEK | -15.71% |
| 2021 Q1 | -1.46 Million SEK | 38.09% |
| 2021 Q2 | -2.15 Million SEK | -47.51% |
| 2021 Q4 | -2.44 Million SEK | -68.2% |
| 2020 Q2 | -1.12 Million SEK | 36.7% |
| 2020 FY | -6.49 Million SEK | -5.2% |
| 2020 Q4 | -2.36 Million SEK | -90.32% |
| 2020 Q3 | -1.24 Million SEK | -10.38% |
| 2020 Q1 | -1.77 Million SEK | 37.46% |
| 2019 Q1 | -1.17 Million SEK | 45.3% |
| 2019 Q4 | -2.83 Million SEK | -366.8% |
| 2019 Q2 | -1.56 Million SEK | -33.33% |
| 2019 Q3 | -608.01 Thousand SEK | 61.04% |
| 2019 FY | -6.17 Million SEK | -47.43% |
| 2018 Q2 | -733.74 Thousand SEK | 14.26% |
| 2018 Q1 | -855.82 Thousand SEK | 8.62% |
| 2018 FY | -4.19 Million SEK | -68.28% |
| 2018 Q4 | -2.14 Million SEK | -364.78% |
| 2018 Q3 | -460.46 Thousand SEK | 37.24% |
| 2017 Q3 | -136.95 Thousand SEK | 74.47% |
| 2017 Q2 | -536.38 Thousand SEK | 39.05% |
| 2017 Q1 | -880.08 Thousand SEK | 39.88% |
| 2017 FY | -2.48 Million SEK | 15.75% |
| 2017 Q4 | -936.54 Thousand SEK | -583.85% |
| 2016 Q2 | -685.78 Thousand SEK | -145.05% |
| 2016 Q4 | -1.46 Million SEK | -172.34% |
| 2016 Q1 | -279.85 Thousand SEK | 87.03% |
| 2016 FY | -2.95 Million SEK | 13.2% |
| 2016 Q3 | -537.53 Thousand SEK | 21.62% |
| 2015 Q4 | -2.15 Million SEK | -313.54% |
| 2015 Q1 | -263.51 Thousand SEK | -505.62% |
| 2015 FY | -3.4 Million SEK | -640.91% |
| 2015 Q3 | -521.68 Thousand SEK | -12.85% |
| 2015 Q2 | -462.27 Thousand SEK | -75.43% |
| 2014 FY | -459.55 Thousand SEK | -38.36% |
| 2014 Q4 | -43.51 Thousand SEK | 0.0% |
| 2013 FY | -332.14 Thousand SEK | 82.18% |
| 2012 FY | -1.86 Million SEK | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Asarina Pharma AB (publ) | -14.64 Million SEK | -12.855% |
| BioArctic AB (publ) | 252.64 Million SEK | 106.54% |
| Modus Therapeutics Holding AB (publ) | -16.4 Million SEK | -0.738% |
| CombiGene AB (publ) | -36.3 Million SEK | 54.491% |
| Diamyd Medical AB (publ) | -146.56 Million SEK | 88.727% |
| Elicera Therapeutics AB (publ) | -17.09 Million SEK | 3.359% |
| OncoZenge AB (publ) | -15.9 Million SEK | -3.899% |
| Alligator Bioscience AB (publ) | -248.98 Million SEK | 93.364% |
| Calliditas Therapeutics AB (publ) | -384.39 Million SEK | 95.702% |
| Mendus AB (publ) | -100.65 Million SEK | 83.585% |
| LIDDS AB (publ) | -40.67 Million SEK | 59.379% |
| Lipum AB (publ) | -37.25 Million SEK | 55.65% |
| Magle Chemoswed Holding AB (publ) | 18 Million SEK | 191.743% |
| Simris Alg AB (publ) | -36.63 Million SEK | 54.901% |
| Spago Nanomedical AB (publ) | -42.5 Million SEK | 61.129% |
| Stayble Therapeutics AB (publ) | -23.95 Million SEK | 31.027% |
| Xbrane Biopharma AB (publ) | -310.42 Million SEK | 94.678% |
| Xspray Pharma AB (publ) | -180.76 Million SEK | 90.86% |
| Ziccum AB (publ) | -21.56 Million SEK | 23.367% |
| AcouSort AB (publ) | -17.48 Million SEK | 5.518% |
| Active Biotech AB (publ) | -46.48 Million SEK | 64.457% |
| Amniotics AB (publ) | -29.07 Million SEK | 43.171% |
| Camurus AB (publ) | 532.35 Million SEK | 103.104% |
| Cantargia AB (publ) | -290.01 Million SEK | 94.303% |
| Scandinavian ChemoTech AB (publ) | -20.13 Million SEK | 17.96% |
| Genovis AB (publ.) | 54.22 Million SEK | 130.47% |
| Guard Therapeutics International AB (publ) | -115.07 Million SEK | 85.642% |
| Isofol Medical AB (publ) | -41.68 Million SEK | 60.363% |
| Intervacc AB (publ) | -93.57 Million SEK | 82.344% |
| Kancera AB (publ) | -65.04 Million SEK | 74.598% |
| Karolinska Development AB (publ) | -3.5 Million SEK | -371.384% |
| Lipigon Pharmaceuticals AB (publ) | -12.37 Million SEK | -33.554% |
| NextCell Pharma AB | -43.17 Million SEK | 61.73% |
| Saniona AB (publ) | -81.06 Million SEK | 79.619% |
| Vicore Pharma Holding AB (publ) | -321.5 Million SEK | 94.861% |
| Xintela AB (publ) | -57.23 Million SEK | 71.135% |
| Sprint Bioscience AB (publ) | -845 Thousand SEK | -1855.266% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | -15.51 Million SEK | -6.511% |
| Corline Biomedical AB | -1.78 Million SEK | -824.049% |
| IRLAB Therapeutics AB (publ) | -180.76 Million SEK | 90.86% |
| Bio-Works Technologies AB (publ) | -55.41 Million SEK | 70.186% |
| Aptahem AB (publ) | -10.1 Million SEK | -63.507% |
| Infant Bacterial Therapeutics AB (publ) | -134.61 Million SEK | 87.727% |
| Fluicell AB (publ) | -26.87 Million SEK | 38.532% |
| Biovica International AB (publ) | -126.07 Million SEK | 86.895% |
| Abliva AB (publ) | -96.54 Million SEK | 82.887% |
| Egetis Therapeutics AB (publ) | -324.8 Million SEK | 94.913% |
| 2cureX AB (publ) | -36.36 Million SEK | 54.564% |
| I-Tech AB | 24.43 Million SEK | 167.616% |
| Hansa Biopharma AB (publ) | -788.49 Million SEK | 97.905% |
| Cyxone AB (publ) | -21.66 Million SEK | 23.725% |
| ExpreS2ion Biotech Holding AB (publ) | -105.96 Million SEK | 84.408% |
| Biosergen AB | -27.26 Million SEK | 39.402% |
| Nanologica AB (publ) | -69.96 Million SEK | 76.385% |
| SynAct Pharma AB | -224.49 Million SEK | 92.64% |
| Annexin Pharmaceuticals AB (publ) | -44.17 Million SEK | 62.6% |
| BioInvent International AB (publ) | -369.94 Million SEK | 95.534% |
| Oncopeptides AB (publ) | -253.44 Million SEK | 93.481% |
| Pila Pharma AB (publ) | -6.39 Million SEK | -158.429% |
| Ascelia Pharma AB (publ) | -110.91 Million SEK | 85.104% |
| Diagonal Bio AB (publ) | -11.56 Million SEK | -42.85% |